After selling his last company to Teladoc in a whopping $18.5 billion deal, all eyes are on how Glen Tullman will use M&A to unlock value at Transcarent, last valued at $1.62 billion.
Driving the news: Sarah, during a fireside chat at ATA2022, asked Tullman whether the consumer-directed health care startup would consider buying care navigation company Accolade given its recent performance (despite its use of a model Tullman disavows).
